Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


Shares of clinical-stage bio pharmaceutical company Altimmune, Inc. (ALT) are down more than 6% Thursday morning after the company said that the FDA has issued a clinical hold on the Investigational New Drug (IND) application for its Covid-19 vaccine candidate, AdCOVID.


RTTNews | Dec 24, 2020 10:05AM EST

10:04 Thursday, December 24, 2020 (RTTNews.com) - Shares of clinical-stage bio pharmaceutical company Altimmune, Inc. (ALT) are down more than 6% Thursday morning after the company said that the FDA has issued a clinical hold on the Investigational New Drug (IND) application for its Covid-19 vaccine candidate, AdCOVID.

The regulator asked the company for some protocol changes and also sought additional data on AdCOVID's chemistry, manufacturing and controls.

Altimmune said it has responded to the Agency's clinical hold letter received on December 22, 2020, does not see a significant impact on the overall clinical development timeline as the Company has agreed to each of the FDA's requests.

ALT, currently at $11.75, has been trading in the range of $1.60- $35.1 in the last one year.

Read the original article on RTTNews ( https://www.rttnews.com/3156133/stock-alert-altimmune-loses-6.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC